Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. MAO-A compound I14
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. MAO-A compound I14: sourced facts only. name: "Among all inhibitors, I14 exhibited the best inhibitory activities against 5-HT2AR and MAO-A." [PMID:36173886]; target: "Among all inhibitors, I14 exhibited the best inhibitory activities against 5-HT2AR and MAO-A." [PMID:36173886]; developer: "State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing210009, China." [PMID:36173886]; stage: "I14 also significantly ameliorated the depression-like behavior of zebrafish and mice." [PMID:36173886]
02
Targets
MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on China Pharma Univ. MAO-A compound I14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. MAO-A compound I14.